1 December 2016 - The 1 December 2016 issue of the Schedule of Pharmaceutical Benefits sees a number of new and revised listings.

The new/revised listings are:

• Adalimumab (Humira) - new indication
  
• Aflibercept (Eylea) - new indication
• Apomorphine hydrochloride (Movapro PFS) - new formulation
  
• Buprenorphine (Norspan) - restriction change
  
• Emtricitabine with tenofovir alafenamide fumarate (Descovy) - new combination product
  
• Evolocumab (Repatha) - new medicine
  
• Ipilimumab (Yervoy) - restriction change
  
• Lenvatinib mesylate (Lenvima) - new medicine
  
• Bicalutamide with leuprorelin acetate (Bi Eligard CP) - new combination product
  
• Ocriplasmin (Jetrea) - new medicine
  
• Omalizumab (Xolair) - new indication
  
• Tocilizumab (Actemra) - new formulation
  

Read summary of changes